News
CASI
--
0.00%
--
BRIEF-CASI Pharma Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma
reuters.com · 06/10 11:33
CASI Pharmaceuticals Doses First Patient in Early-Stage Study of Potential Multiple Myeloma Drug
MT Newswires · 06/10 07:52
Need To Know: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Simply Wall St. · 06/10 06:06
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference
and , /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. , Chairman and Chief Executive Officer of C...
PR Newswire - PRF · 05/27 11:01
Return On Capital Employed Overview: CASI Pharmaceuticals
CASI Pharmaceuticals (NASDAQ:CASI) reported Q1 sales of $5.74 million. Earnings fell to a loss of $15.60 million, resulting in a 1.97% decrease from last quarter. In Q4, CASI Pharmaceuticals brought in $4.82 million in sales but lost $15.91 million in earn...
Benzinga · 05/21 16:43
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 05/20 20:37
Surface Oncology, Mustang Bio among top picks as BTIG turns bullish on cell and gene therapy space
“We are bullish on the cell and gene therapy space,” noted BTIG analyst Justin Zelin highlighting the importance of stock picking in the area given “the limited targets and indications
Seekingalpha · 05/18 14:50
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
 
Benzinga · 05/18 14:05
BTIG Initiates Coverage On CASI Pharmaceuticals with Buy Rating, Announces Price Target of $4
BTIG analyst Justin Zelin initiates coverage on CASI Pharmaceuticals (NASDAQ:CASI) with a Buy rating and announces Price Target of $4.
Benzinga · 05/18 11:42
--BTIG Initiates CASI Pharmaceuticals at Buy Rating With $4 Price Target
MT Newswires · 05/18 09:07
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating CASI Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims
NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of CASI Pharmaceuticals, Inc. .
ACCESSWIRE · 05/17 14:22
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Raises Price Target to $4
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and raises the price target from $3.5 to $4.
Benzinga · 05/14 10:40
--HC Wainwright Adjusts CASI Pharmaceuticals PT to $4 From $3.50, Maintains Buy Rating
MT Newswires · 05/14 10:21
BRIEF-CASI Pharmaceuticals Announces Q1 Revenue Of $5.7 Mln
reuters.com · 05/13 12:32
CASI Pharmaceuticals: Q1 Earnings Insights
  Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 22.22% year over year to ($0.11), which missed the estimate of ($0.06).
Benzinga · 05/13 11:27
CASI Pharmaceuticals EPS misses by $0.05, beats on revenue
CASI Pharmaceuticals (CASI): Q1 GAAP EPS of -$0.11 misses by $0.05.Revenue of $5.74M (+68.3% Y/Y) beats by $0.69M.As of March 31, 2021, the Company had cash and cash equivalents of
Seekingalpha · 05/13 11:10
CASI Pharmaceuticals Q1 EPS $(0.11) Misses $(0.06) Estimate, Sales $5.74M Beat $5.05M Estimate
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 22.22 percent decrease over losses of $(0.09) per share
Benzinga · 05/13 11:03
CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2021.
PR Newswire · 05/13 11:00
CASI Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:00 AM Eastern Time.
ACCESSWIRE · 05/13 09:45
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 05/13 08:15
Webull provides a variety of real-time CASI stock news. You can receive the latest news about CASI Pharms through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).